Publications by authors named "M Fellmann"
Background: Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). It is known that non-serious treatment-emergent adverse events (TEAEs) may not lead to UC drug discontinuation but can affect treatment tolerability.
Objectives: This post hoc analysis evaluated the incidence of specific, common, non-serious TEAEs reported in the etrasimod UC clinical programme and the characteristics of affected patients.
Article Synopsis
- Etrasimod is an oral medication aimed at treating moderately to severely active ulcerative colitis (UC), and this study focused on its impact on patients' health-related quality of life (HRQoL).
- The analysis used data from two Phase 3 clinical trials and assessed HRQoL using various questionnaires at different time points.
- Results showed that patients taking etrasimod experienced significantly greater improvements in HRQoL measures compared to those on a placebo, especially among certain patient groups, indicating the medication's effectiveness.
Article Synopsis
- * Key discussions included the prevalence of AD, advancements in treatment and management, and the importance of considering environmental and lifestyle factors affecting patients.
- * The forum emphasizes the need for increased awareness and collaboration among stakeholders to close the gap between research advancements and practical applications in patient care.
Article Synopsis
- Biomarkers like fecal calprotectin (fCAL) and high-sensitivity C-reactive protein (hsCRP) may be useful in tracking ulcerative colitis (UC) progression and treatment response, potentially replacing endoscopies.
- In the ELEVATE UC clinical trials, patients receiving the drug etrasimod showed significant differences in fCAL and hsCRP levels compared to those on placebo, correlating with better clinical outcomes.
- The results indicated that lower levels of fCAL and hsCRP after treatment with etrasimod are predictive of effective long-term responses in patients with moderately to severely active UC.
Background: Abrocitinib efficacy by comorbidity status in patients with moderate-to-severe atopic dermatitis (AD) has not been previously assessed. This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with AD and allergic comorbidities.
Methods: Data were pooled from patients who received abrocitinib 200 mg, 100 mg, or placebo in phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials.